Gain Therapeutics Inc (GANX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $46.31M
Last updated: Nov 17, 2026 at 11:06 AM ET
Gain Therapeutics Inc (GANX) Stock Forecast
Analysts expect Gain Therapeutics (GANX) to earn -$0.40 per share in the fiscal year ending Dec 31, 2026. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.63.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 20.0% |
| Buy | 4 | 80.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.40
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.63
- EPS consensus
- Next report
- Mar 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.40 | -$0.41 to -$0.38 | 2 |
| Dec 31, 2027 | -$0.63 | -$1.00 to -$0.35 | 4 |
Quarterly Estimates
The EPS consensus rises from -$0.13 for the quarter ending Dec 31, 2026 to -$0.12 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.13 | -$0.16 to -$0.08 | 6 |
| Mar 31, 2027 | -$0.12 | -$0.13 to -$0.11 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.59.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.40 | -$0.51 | -$0.51 | -$0.50 | -$0.59 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.63 | -$0.69 | -$0.69 | -$0.55 | -$0.57 | N/A |
| Quarter ending Mar 31, 2027 | -$0.12 | -$0.13 | -$0.13 | -$0.13 | -$0.13 | N/A |
Frequently Asked Questions About GANX
What is the GANX stock forecast?
Consensus analyst estimates put Gain Therapeutics's EPS at -$0.40 for the fiscal year ending Dec 31, 2026. The consensus rating from 5 analysts is Buy.
How do analysts rate GANX stock?
Of 5 analysts covering Gain Therapeutics, 1 rates it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from GANX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.40, with estimates from -$0.41 to -$0.38 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.63, with estimates from -$1.00 to -$0.35 from 4 analysts.
How many analysts cover GANX?
5 analysts rate Gain Therapeutics stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
GANX pages: Overview, Earnings, Forecast, Financials, Competitors